147 related articles for article (PubMed ID: 19926362)
1. Anticancer activity of dinuclear gallium(III) carboxylate complexes.
Kaluderović MR; Gómez-Ruiz S; Gallego B; Hey-Hawkins E; Paschke R; Kaluderović GN
Eur J Med Chem; 2010 Feb; 45(2):519-25. PubMed ID: 19926362
[TBL] [Abstract][Full Text] [Related]
2. Study of the cytotoxicity and particle action in human cancer cells of titanocene-functionalized materials with potential application against tumors.
García-Peñas A; Gómez-Ruiz S; Pérez-Quintanilla D; Paschke R; Sierra I; Prashar S; del Hierro I; Kaluđerović GN
J Inorg Biochem; 2012 Jan; 106(1):100-10. PubMed ID: 22112846
[TBL] [Abstract][Full Text] [Related]
3. Expanding monomeric pyrophosphate complexes beyond platinum.
Marino N; Vortherms AR; Hoffman AE; Doyle RP
Inorg Chem; 2010 Aug; 49(15):6790-2. PubMed ID: 20429603
[TBL] [Abstract][Full Text] [Related]
4. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
5. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity, apoptosis and study of the DNA-binding properties of bi- and tetranuclear gallium(III) complexes with heterocyclic thiolato ligands.
Gallego B; Kaluđerović MR; Kommera H; Paschke R; Hey-Hawkins E; Remmerbach TW; Kaluđerović GN; Gómez-Ruiz S
Invest New Drugs; 2011 Oct; 29(5):932-44. PubMed ID: 20467884
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands.
Vrzal R; Starha P; Dvorák Z; Trávnícek Z
J Inorg Biochem; 2010 Oct; 104(10):1130-2. PubMed ID: 20673688
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
[TBL] [Abstract][Full Text] [Related]
9. New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity.
Galal SA; Hegab KH; Kassab AS; Rodriguez ML; Kerwin SM; el-Khamry AM; el-Diwani HI
Eur J Med Chem; 2009 Apr; 44(4):1500-8. PubMed ID: 18752870
[TBL] [Abstract][Full Text] [Related]
10. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of Gd(III)- and Dy(III)-complexes.
Kostova I; Kiefer W; Momekov G
Arch Pharm (Weinheim); 2007 Dec; 340(12):642-9. PubMed ID: 17994606
[TBL] [Abstract][Full Text] [Related]
12. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and crystal structure of two new dinuclear cobalt(II) complexes interaction with HeLa cells.
Gao EJ; Gao XN; Guan F; Zhu MC; Liu L; Zhang M; Zhang YX; Wang Y; Wen Z; Zhang Y; Zhang Y; Liang Q
Eur J Med Chem; 2011 Jan; 46(1):160-7. PubMed ID: 21093965
[TBL] [Abstract][Full Text] [Related]
14. Self-assembly and cytotoxicity study of waterwheel-like dinuclear metal complexes: the first metal complexes appended with multiple free hydroxamic acid groups.
Wang WH; Liu WS; Wang YW; Li Y; Zheng LF; Wang DQ
J Inorg Biochem; 2007 Feb; 101(2):297-304. PubMed ID: 17125839
[TBL] [Abstract][Full Text] [Related]
15. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
16. Large-bite bis(phosphite) ligand containing mesocyclic thioether moieties: synthesis, reactivity, group 11 (Cu(I), Au(I)) metal complexes and anticancer activity studies on a human cervical cancer (HeLa) cell line.
Suresh D; Balakrishna MS; Rathinasamy K; Panda D; Mague JT
Dalton Trans; 2008 May; (17):2285-92. PubMed ID: 18414753
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes.
Sorasaenee K; Fu PK; Angeles-Boza AM; Dunbar KR; Turro C
Inorg Chem; 2003 Feb; 42(4):1267-71. PubMed ID: 12588165
[TBL] [Abstract][Full Text] [Related]
18. Gallium(III) complexes of 2-pyridineformamide thiosemicarbazones: cytotoxic activity against malignant glioblastoma.
Mendes IC; Soares MA; Dos Santos RG; Pinheiro C; Beraldo H
Eur J Med Chem; 2009 May; 44(5):1870-7. PubMed ID: 19070402
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.
Calamai P; Carotti S; Guerri A; Mazzei T; Messori L; Mini E; Orioli P; Speroni GP
Anticancer Drug Des; 1998 Jan; 13(1):67-80. PubMed ID: 9474243
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization and assessment of the cytotoxic properties of cis and trans-[Pd(L)(2)Cl(2)] complexes involving 6-benzylamino-9-isopropylpurine derivatives.
Trávnícek Z; Szucová L; Popa I
J Inorg Biochem; 2007 Mar; 101(3):477-92. PubMed ID: 17208304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
